Compare GKOS & NYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | NYT |
|---|---|---|
| Founded | 1998 | 1851 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.1B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | NYT |
|---|---|---|
| Price | $173.00 | $63.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $198.69 | $78.56 |
| AVG Volume (30 Days) | 723.3K | ★ 3.0M |
| Earning Date | 10-28-2026 | 11-27-2026 |
| Dividend Yield | N/A | ★ 1.44% |
| EPS Growth | N/A | ★ 18.08 |
| EPS | N/A | ★ 1.11 |
| Revenue | $507,442,000.00 | ★ $1,783,639,000.00 |
| Revenue This Year | $36.18 | $11.16 |
| Revenue Next Year | $23.04 | $7.08 |
| P/E Ratio | ★ N/A | $57.72 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $54.10 |
| 52 Week High | $191.62 | $87.10 |
| Indicator | GKOS | NYT |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 42.06 |
| Support Level | $148.39 | $62.40 |
| Resistance Level | $184.68 | $73.27 |
| Average True Range (ATR) | 6.50 | 2.37 |
| MACD | 1.09 | -0.19 |
| Stochastic Oscillator | 89.32 | 19.80 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company derives revenue from subscriptions, advertising, and other sources, where the majority of its revenue is generated through subscriptions, which consist of income from standalone and multiproduct bundle subscriptions to its digital products and subscriptions to and single-copy and bulk sales of print products.